Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Protalix Biotherapeutics Inc maintains a gross margin of 53.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.94%, while the net margin is 13.19%. These profitability ratios, combined with a Return on Equity (ROE) of 12.64%, provide a clear picture of how effectively PLX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PLX competes directly with industry leaders such as ARCT and NVCT. With a market capitalization of $243.68M, it holds a leading position in the sector. When comparing efficiency, PLX's gross margin of 53.37% stands against ARCT's 100.00% and NVCT's N/A. Such benchmarking helps identify whether Protalix Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
